SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Tune Therapeutics
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine.
